[go: up one dir, main page]

NI201000211A - Dronedarona para la prevención de la fibrilación auricular permanente. - Google Patents

Dronedarona para la prevención de la fibrilación auricular permanente.

Info

Publication number
NI201000211A
NI201000211A NI201000211A NI201000211A NI201000211A NI 201000211 A NI201000211 A NI 201000211A NI 201000211 A NI201000211 A NI 201000211A NI 201000211 A NI201000211 A NI 201000211A NI 201000211 A NI201000211 A NI 201000211A
Authority
NI
Nicaragua
Prior art keywords
dronedarone
prevention
atrial fibrillation
permanent atrial
permanent
Prior art date
Application number
NI201000211A
Other languages
English (en)
Inventor
Gaudin Christophe
Hamdani Nacéra
Radzik Davide
Van Eickels Martin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39731657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201000211(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NI201000211A publication Critical patent/NI201000211A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la fibrilación auricular permanente.
NI201000211A 2008-06-10 2010-12-06 Dronedarona para la prevención de la fibrilación auricular permanente. NI201000211A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6026308P 2008-06-10 2008-06-10
EP08290531A EP2133074A1 (en) 2008-06-10 2008-06-10 Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation

Publications (1)

Publication Number Publication Date
NI201000211A true NI201000211A (es) 2011-04-27

Family

ID=39731657

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000211A NI201000211A (es) 2008-06-10 2010-12-06 Dronedarona para la prevención de la fibrilación auricular permanente.

Country Status (24)

Country Link
US (1) US20110166220A1 (es)
EP (2) EP2133074A1 (es)
JP (1) JP2011522876A (es)
KR (1) KR20110026422A (es)
CN (1) CN102056603A (es)
AR (1) AR072069A1 (es)
AU (1) AU2009259009A1 (es)
CA (1) CA2727326A1 (es)
CL (1) CL2010001422A1 (es)
CO (1) CO6280479A2 (es)
CR (1) CR11829A (es)
DO (1) DOP2010000365A (es)
EA (1) EA201071378A1 (es)
EC (1) ECSP10010666A (es)
IL (1) IL209791A0 (es)
MA (1) MA32462B1 (es)
MX (1) MX2010013698A (es)
NI (1) NI201000211A (es)
PE (1) PE20110055A1 (es)
SV (1) SV2010003756A (es)
TW (1) TW201002676A (es)
UY (1) UY31886A (es)
WO (1) WO2009150535A1 (es)
ZA (1) ZA201008871B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
AU2009252897B2 (en) 2008-04-17 2015-03-19 Sanofi-Aventis Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
AU2014274638B2 (en) * 2009-12-21 2016-09-15 Gilead Sciences, Inc. Method of treating atrial fibrillation
TWI508726B (zh) * 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
EP2387997A1 (en) * 2010-05-18 2011-11-23 Sanofi Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered
EP2387996A1 (en) * 2010-05-17 2011-11-23 Sanofi Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
AR081392A1 (es) * 2010-05-13 2012-08-29 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para la prevencion de hospitalizaciones cardiovasculares o muerte o sucesos cardiovasculares en pacientes con fibrilacion auricular permanente
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
WO2012020377A1 (en) * 2010-08-11 2012-02-16 Sanofi Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation
WO2012023024A2 (en) * 2010-08-17 2012-02-23 Lupin Limited Controlled release formulations of dronedarone
EP3326616B1 (en) * 2011-06-03 2021-07-28 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
EP2543361A1 (en) * 2011-07-07 2013-01-09 Sanofi Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
FR2977495B1 (fr) * 2011-07-07 2014-03-07 Sanofi Sa Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation
EP2543362A1 (en) * 2011-07-07 2013-01-09 Sanofi Sustained release pharmaceutical oral solid dosage form of dronedarone or one of its pharmaceutically acceptable salts
EP2543363A1 (en) * 2011-07-07 2013-01-09 Sanofi Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
WO2013024411A1 (en) 2011-08-12 2013-02-21 Lupin Limited Co-milled formulation of dronedarone
CN112336445B (zh) * 2019-12-26 2021-11-26 上海微创电生理医疗科技股份有限公司 一种消融系统及其神经探测设备

Also Published As

Publication number Publication date
WO2009150535A1 (en) 2009-12-17
MA32462B1 (fr) 2011-07-03
TW201002676A (en) 2010-01-16
UY31886A (es) 2010-01-29
SV2010003756A (es) 2011-03-15
CO6280479A2 (es) 2011-05-20
CA2727326A1 (en) 2009-12-17
PE20110055A1 (es) 2011-02-11
ZA201008871B (en) 2012-02-29
CN102056603A (zh) 2011-05-11
KR20110026422A (ko) 2011-03-15
JP2011522876A (ja) 2011-08-04
US20110166220A1 (en) 2011-07-07
EA201071378A1 (ru) 2011-06-30
DOP2010000365A (es) 2011-01-15
CL2010001422A1 (es) 2011-05-13
EP2133074A1 (en) 2009-12-16
AU2009259009A1 (en) 2009-12-17
EP2300001A1 (en) 2011-03-30
AR072069A1 (es) 2010-08-04
ECSP10010666A (es) 2011-01-31
IL209791A0 (en) 2011-02-28
WO2009150535A8 (en) 2010-12-23
MX2010013698A (es) 2011-02-23
CR11829A (es) 2011-01-11

Similar Documents

Publication Publication Date Title
NI201000211A (es) Dronedarona para la prevención de la fibrilación auricular permanente.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
SV2010003700A (es) Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
BRPI0919193A2 (pt) Uso de lipídeo, e, composição nutricional
LT3492069T (lt) Farmacinės kompozicijos, apimančios geležies oksihidroksidą
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
TW200942530A (en) Pyridine compounds
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
SV2011003827A (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
NI201000212A (es) Dronedarona para la prevención de la cardioversión.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
IL215551A (en) An indolite derivative, a pharmaceutical preparation containing it and its uses
MX2012007097A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
BR112013010061A2 (pt) "composição farmacêutica, composição e uso"
BRPI0908072A2 (pt) Composição farmacêutica, procedimento de preparação e uso da mesma
IT1393198B1 (it) Polverizzatore rotante.
TN2010000514A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
AR081392A1 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de hospitalizaciones cardiovasculares o muerte o sucesos cardiovasculares en pacientes con fibrilacion auricular permanente
UY31767A (es) Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la hospitalización cardiovascular o de la mortalidad